No. Symbicort is a maintenance inhaler designed for regular use to control asthma. For sudden breathlessness you should use a short-acting bronchodilator such as salbutamol.
Formoterol produces bronchodilation within a few minutes, while budesonide’s anti-inflammatory effects build up over several days. Patients often notice improved ease of breathing within the first week of regular use.
Rinse your mouth with water and spit it out after each inhalation. This removes residual steroid that can promote fungal overgrowth. Maintaining good oral hygiene also helps.
Yes, a short-acting reliever (e.g., salbutamol) is usually prescribed alongside Symbicort for rescue use. Other controller medications should only be added after a prescriber’s evaluation to avoid duplicate dosing.
If you realize the missed dose more than six hours later, take it as soon as possible. If the next scheduled dose is imminent, skip the missed dose and resume the regular schedule. Do not double the dose.
Budesonide is classified as Category B in the UK, indicating limited evidence of risk in humans. It may be used if the clinical benefit outweighs potential risks. Pregnant patients should discuss the decision with their obstetrician.
Yes. Wipe the mouthpiece with a clean, dry cloth regularly to remove powder residue. Do not wash the device with water, as moisture can damage the inhaler mechanism.
You may carry Symbicort in both hand luggage and checked baggage. Keep it in its original packaging, and inform security if asked. The inhaler does not contain lithium batteries and is not prohibited.
Budesonide and formoterol are not prohibited substances in most sporting regulations, but some anti-doping agencies have thresholds for inhaled β₂-agonists. Athletes should disclose inhaler use and consult their sport’s governing body.
The dose counter indicates remaining doses; once it reaches zero, the inhaler should be discarded regardless of the calendar date. Generally, a DPI remains effective for 30 days after opening, but always follow the manufacturer’s stated expiry on the package.
Symbicort Powder is a prescription inhaler that combines two active ingredients-budesonide and formoterol fumarate dihydrate-into a single dry-powder inhaler (DPI). Budesonide is an inhaled corticosteroid that reduces airway inflammation, while formoterol is a long-acting β₂-agonist (LABA) that relaxes airway smooth muscle. In the United Kingdom the product is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) and is available only with a prescription from a qualified prescriber. The inhaler delivers a fixed dose of 160 µg budesonide / 4.5 µg formoterol per inhalation.
Budesonide (corticosteroid)
Enters airway cells and binds glucocorticoid receptors.
Switches off inflammatory genes and promotes the production of anti-inflammatory proteins.
Reduces swelling, mucus production, and the responsiveness of the airway to triggers.
Formoterol (LABA)
Stimulates β₂-adrenergic receptors on airway smooth muscle.
Increases cyclic-AMP, leading to rapid muscle relaxation (onset within minutes) and a sustained bronchodilatory effect that lasts about 12 hours.
Combined effect
The anti-inflammatory action of budesonide lowers the underlying airway hyper-responsiveness, while formoterol provides quick and long-lasting relief from bronchoconstriction.
Together they improve lung function, reduce the frequency of asthma symptoms, and help prevent exacerbations.
Symbicort Powder is approved in the UK for:
Symbicort is not intended for immediate relief of an acute asthma attack; a separate short-acting bronchodilator (e.g., salbutamol) should be kept on hand for rescue use.
Rinsing the mouth with water (without swallowing) after each dose reduces the risk of thrush.
Missed dose - If you remember a missed dose more than 6 hours later, take it as soon as possible. If the next scheduled dose is due within a short time, skip the missed dose-do not double up.
Overdose - Signs may include severe tremor, rapid heart rate, nausea, or dizziness. Seek medical assistance promptly; treatment is supportive and may involve bronchodilator antagonists if severe bronchospasm occurs.
Discontinuation - Long-term high-dose inhaled corticosteroids may require a gradual taper to avoid adrenal insufficiency. Follow your prescriber’s guidance when stopping or reducing therapy.
This article provides educational information about Symbicort Powder and is not a substitute for professional medical advice. Treatment decisions, including the use of any medication for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
